Abstract
Background
There is a paucity of evidence with regard to the safety of contrast medium administration at MRI in neonates and infants.
Purpose
To assess immediate adverse reactions in children younger than 18 months of age during routine clinical utilization of gadoteric acid (Gd-DOTA) in a cohort of patients with nonselected indications.
Materials and methods
One hundred and four neonates and infants were enrolled in a postmarketing survey with Gd-DOTA (Dotarem, Guerbet, Roissy, France) from a single pediatric hospital. A standardized questionnaire was used to collect the patient information.
Results
All included children, ages 3 days to 18 months, received one injection of Gd-DOTA (volume 0.6–4 ml). No immediate adverse event was reported.
Conclusion
This postmarketing study involving neonates and infants suggests a favorable safety profile of Gd-DOTA in routine practice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Burtea C, Laurent S, Vander Elst L et al (2008) Contrast agents: magnetic resonance. Handb Exp Pharmacol 185:135–165
Hanquinet S, Christophe C, Greef DD et al (1996) Clinical evaluation of gadodiamide injection in paediatric MR imaging. Pediatr Radiol 26:806–810
Sadowski EA, Bennett LK, Chan MR et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148–157
Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108
Altun E, Semelka RC, Cakit C (2009) Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol 16:897–905
Janus N, Launay-Vacher V, Karie S et al (2010) Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the finest study. Eur J Radiol 73:357–359
Mendichovszky IA, Marks SD, Simcock CM et al (2008) Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol 38:489–496
Morcos SK (2008) Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 66:175–179
Herve-Somma CM, Sebag GH, Prieur AM et al (1992) Juvenile rheumatoid arthritis of the knee: MR evaluation with Gd-DOTA. Radiology 182:93–98
Bonnerot V, Sebag G, de Montalembert M et al (1994) Gadolinium-DOTA enhanced MRI of painful osseous crises in children with sickle cell anemia. Pediatr Radiol 24:92–95
Ducou le Pointe H, Haddad S, Silberman B et al (1994) Legg-Perthes-Calve disease: staging by MRI using gadolinium. Pediatr Radiol 24:88–91
Hermans R (2006) Head and neck cancer: how imaging predicts treatment outcome. Cancer Imaging 6:S145–153
Hsu WC, Loevner LA, Karpati R et al (2005) Accuracy of magnetic resonance imaging in predicting absence of fixation of head and neck cancer to the prevertebral space. Head Neck 27:95–100
Bartels U, Shroff M, Sung L et al (2006) Role of spinal MRI in the follow-up of children treated for medulloblastoma. Cancer 107:1340–1347
Kobayashi S, Hayakawa K, Nakane T et al (2009) Visualization of intraneural edema using gadolinium-enhanced magnetic resonance imaging of carpal tunnel syndrome. J Orthop Sci 14:24–34
Drape JL, Thelen P, Gay-Depassier P et al (1993) Intraarticular diffusion of Gd-DOTA after intravenous injection in the knee: MR imaging evaluation. Radiology 188:227–234
Willinek WA, Schild HH (2008) Clinical advantages of 3.0 T MRI over 1.5 T. Eur J Radiol 65:2–14
Riccabona M, Simbrunner J, Ring E et al (2002) Feasibility of MR urography in neonates and infants with anomalies of the upper urinary tract. Eur Radiol 12:1442–1450
Herborn CU, Honold E, Wolf M et al (2007) Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 42:58–62
Briand Y, Neiss AC, Vitry A (1992) Efficacy and safety of the macrocyclic complex Gd-DOTA in children: results of a multi-centre study. In: 29th congress of the European Society of Pediatric Radiology, Budapest: R12.
Shellock FG, Parker JR, Pirovano G et al (2006) Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging 24:1378–1385
Kuo PH, Kanal E, Abu-Alfa AK et al (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242:647–649
Grobner T (2008) Prischl FC (2008) Patient characteristics and risk factors for nephrogenic systemic fibrosis for gadolinium exposure. Semin Dial 21:135–139
Idee JM, Port M, Dencausse A et al (2009) Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin N Am 47:855–869
Acknowledgments
This study was partially supported by, and data analysis was performed by, the Guerbet group, Roissy, France. The authors have no conflicts of interest that are directly relevant to the contents of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Emond, S., Brunelle, F. Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions. Pediatr Radiol 41, 1401–1406 (2011). https://doi.org/10.1007/s00247-011-2167-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00247-011-2167-3